Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Cullinan Therapeutics Inc shares valued at $43,682 were sold by Michaelson Jennifer on Dec 12 ’24. At $12.52 per share, Michaelson Jennifer sold 3,489 shares. The insider’s holdings dropped to 104,453 shares worth approximately $1.12 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Michaelson Jennifer sold 8,000 shares, netting a total of over 125,120 in proceeds. Following the sale of shares at $15.64 each, the insider now holds 107,942 shares.
Before that, Michaelson Jennifer had sold 8,000 shares from its account. In a trade valued at $144,720, the Chief Scientific Officer traded Cullinan Therapeutics Inc shares for $18.09 each. Upon closing the transaction, the insider’s holdings decreased to 8,000 shares, worth approximately $1.25 million.
As published in their initiating research note from UBS on October 24, 2024, Cullinan Therapeutics Inc [CGEM] has been a Buy and the price target has been revised to $30. Analysts at Stifel started covering the stock with ‘”a Buy”‘ outlook in a report released in early May. As of April 15, 2024, William Blair has initiated its “an Outperform” rating for CGEM. Earlier on February 15, 2024, Wedbush initiated its rating. Their recommendation was “an Outperform” for CGEM stock.
Analyzing CGEM Stock Performance
During the last five days, there has been a drop of approximately -13.98%. Over the course of the year, Cullinan Therapeutics Inc shares have jumped approximately 5.69%. Shares of the company reached a 52-week high of $30.19 on 05/07/24 and a 52-week low of $10.00 on 01/11/24. A 50-day SMA is recorded $14.52, while a 200-day SMA reached $17.91. Nevertheless, trading volume fell to 0.74 million shares from 0.35 million shares the previous day.
Support And Resistance Levels for Cullinan Therapeutics Inc (CGEM)
According to the 24-hour chart, there is a support level at 10.35, which, if violated, would cause prices to drop to 9.92. In the upper region, resistance lies at 11.35. The next price resistance is at 11.92. RSI (Relative Strength Index) is 27.09 on the 14-day chart, showing oversold technical sentiment. Moving Average Convergence Divergence (MACD) is at -1.05, which suggests the price will decrease in the coming days. Percent R is at 91.77%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.
